Tumor necrosis factor α-induced stimulation of neoplastic progression of preneoplastic, hyperplastic alveolar nodule line C4

International Journal of Oncology

Volumn 10, Issue 6, 1997, Pages 1209-1215

  Tsai, S C Jane ^a,b   Miller, Bonnie E ^a   Jones, Richard F ^a   Heppner, Gloria H ^a  

^a KARMANOS CANCER INSTITUTE   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

Author keywords

hyperplastic alveolar nodule; mammary cell growth; preneoplasia; progression; Tumor necrosis factor

Indexed keywords

LYMPHOTOXIN; MESSENGER RNA; RECOMBINANT INTERLEUKIN 2; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BREAST ADENOCARCINOMA; BREAST CARCINOGENESIS; BREAST EPITHELIUM; BREAST HYPERPLASIA; CANCER GROWTH; CELL CULTURE; CELL LINE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRECANCER; PRIORITY JOURNAL; SPLEEN CELL; TISSUE TRANSPLANTATION;

EID: 0030950984     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Clarke R, Dickson RB and Lippman ME: Hormonal aspects of breast cancer. Growth factors, drugs and stromal interactions. Crit Rev Oncol/Hematol 12: 1-23, 1992.
2. Tsai SJ, Loeffler D and Heppner GH: Associated effects of bromocriptine on neoplastic progression of mouse mammary preneoplastic hyperplastic alveolar nodule (HAN) line C4 and on HAN-infiltrating and splenic lymphocyte function. Cancer Res 52: 2209-2215, 1992.
3. Wei W-Z, Fulton A, Winkelhake J and Heppner G: Correlation of natural killer activity with tumorigenesis of a preneoplastic mouse mammary lesion. Cancer Res 49: 2709-2715, 1989.
4. Stewart THM and Tsai S-CJ: A review of the possible role of immunostimulation in worsening the prognosis of a subset of patients with breast cancer. Clin Exp Metastasis 11: 295-305, 1993.
5. Michiel DF and Oppenheim JJ: Cytokines as positive and negative regulators of tumor promotion and progression. Semin Cancer Biol 3: 3-15, 1992.
6. Schwartzentruber DJ, Solomon D, Rosenberg SA and Topalian SL: Characterization of lymphocytes infiltrating human breast cancer: specific immune reactivity detected by measuring cytokine secretion. J Immunother 12: 1-12, 1992.
7. Vitolo D, Zerbe T, Kanbour A, Dahl C, Herberman R and Whiteside TL: Expression of mRNA for cytokines in tumor-infiltrating mononuclear cells in ovarian adenocarcinoma and invasive breast cancer. Int J Cancer 51: 573-580, 1992.
8. Wei W-Z, Malone K, Mahoney K and Heppner GH: Characterization of lymphocytic infiltrates in normal, preneoplastic and neoplastic mouse mammary tissues. Cancer Res 46: 2680-2685, 1986.
9. Miller FR, McEachern D and Miller BE: Growth regulation of mouse mammary tumor cells in collagen gel cultures by diffusible factors produced by normal mammary gland epithelium and stromal fibroblasts. Cancer Res 49: 6091-6097, 1989.
10. Medina D: Preneoplastic lesions in mouse mammary tumorigenesis. Meth Cancer Res 7: 3-53, 1973.
11. Tsai S-CJ, Gansbacher B, Gill R, Tait L, Miller FR, Wei W-Z and Heppner GH: Antitumor immunity induced by interleukin-2 gene transduced mouse mammary tumor cells versus transduced mammary stromal fibroblasts. J Natl Cancer Inst 85: 546-553, 1993.
12. Yamamura M, Modlin RL, Ohmen JD and Moy R: Local expression of antiinflammatory cytokines in cancer. J Clin Invest 91: 1005-1010, 1993.
13. Baum B: The role of endocrine therapy in primary breast cancer. J Steroid Biochem 36: 187-189, 1990.
14. van Netten JP, Ashmead BJ, Cavers D, Fletcher C, Thornton IG, Antonsen BL, Coy P and Brigden ML: 'Macrophages' and their putative significance in human breast cancer. Br J Cancer 66: 220-221, 1992.
15. Early Breast Cancer Trialist's Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 339: 71-85, 1992.
16. Stewart THM, Retsky MW, Tsai S-CJ and Verma S: Dose response in the treatment of breast cancer. Lancet 343: 402-404, 1994.
17. Stewart THM, Tsai S-CJ, Grayson H, Henderson R and Opelz G: Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation. Lancet 346: 796-798, 1995.
18. Prehn RT: Stimulatory effects of immune reactions upon the growth of untransplanted tumors: tumor development. Cancer Res 54: 908-914, 1994.
19. Ogmundsdottir HM, Petursdottir I and Gudmundsdottir I: Interactions between the immune system and breast cancer. Acta Oncol 34: 647-650, 1995.
20. Blalock JE and Smith EM: A molecular basis for interactions between the immune and neuroendocrine systems. Int J Neurosci 38: 455-464, 1988.
21. Ip MM, Shoemaker SF and Darcy KM: Regulation of rat mammary epithelial cell proliferation and differentiation by tumor necrosis factor-α. Endocrinology 130: 2833-2840, 1992.
22. Torreele E and De Baetselier P: Multiple effects of TNF-α on Lewis lung carcinoma cells: acquisition of TNF-α resistance, decreased MHC expression, increased malignant behavior and a dramatic shift in the metastatic pattern. Clin Exp Metastasis 14 (Suppl 1): 44, 1996.
23. Torreele E and De Baetselier P: Progression of Lewis lung carcinoma tumors is manifested in increased TNF-α resistance, reduced MHC expression, enhanced tumorigenicity and an increased ability for both lung and extra-pulmonary metastases: possible involvment of TNF-α. Clin Exp Metastasis 14 (Suppl 1): 40, 1996.
24. Kronke M, Hensel G, Schluter C, Scheurich P, Schutze S and Pfizenmaier K: Tumor necrosis factor and lymphotoxin gene expression in human tumor cell lines. Cancer Res 48: 5417-5421, 1988.
25. Spriggs D, Imamura K, Rodriguez C, Horiguch J and Kufe DW: Induction of tumor necrosis factor expression and resistance in a human breast tumor cell line. Proc Natl Acad Sci USA 84: 6563-6566, 1987.
26. Mallmann P, Diedrich K, Mallmann R, Koenig UD and Krebs D: Determination of TNFα, Interferon α, interleukin 2 and reactivity in the leucocyte migration inhibition test in breast cancer patients. Anticancer Res 11: 1509-1516, 1991.
27. Nakazaki H: Preoperative and postoperative cytokines in patients with cancer. Cancer 70: 709-713, 1992.
28. Nakashima J, Tachibana M, Ueno M, Baba S and Tazaki H: Tumor necrosis factor and coagulopathy in patients with prostate cancer. Cancer Res 55: 4881-4885, 1995.
29. Balkwill F, Osborne R, Burke F, Naylor S, Talbot D, Durbin H, Tavernier J and Fiers W: Evidence for tumor necrosis factor/cachectin production in cancer. Lancet 2: 1229-1232, 1987.
30. Ennsoli B, Barillari G and Gallo RC: Cytokines and growth factors in the pathogenesis of Aids-associated Kaposi's sarcoma. Immunol Rev 127: 147-155, 1992.
31. Vukanovic J and Isaacs JT: Linomide inhibits angiogenesis, growth, metastasis and macrophage infiltration within rat prostatic cancers. Cancer Res 55: 1499-1504, 1995.
32. Rosen EM, Goldberg ID, Liu D, Setter E, Donovan MA, Bhargava M, Reiss M and Kacinski BM: Tumor necrosis factor stimulates epithelial tumor cell motility. Cancer Res 51: 5315-5321, 1991.